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Cancer genomic DNA sequences enable identification of all mutations and suggest targets for precision medicine.
The identities and patterns of the mutations themselves also provide critical information for deducing the originating
DNA damaging agents, causal molecular mechanisms, and thus additional therapeutic targets. A classic example is
ultraviolet light, which crosslinks adjacent pyrimidines and leads to C-to-T transitions. A new example is the DNA
cytosine deaminase APOBEC3B, which was identified recently as a source of DNA damage and mutagenesis in breast,
head/neck, cervix, bladder, lung, ovary, and to lesser extents additional cancer types. This enzyme is normally an
effector protein in the innate immune response to virus infection but upregulation in these cancer types causes
elevated levels of genomic C-to-U deamination events, which manifest as C-to-T transitions and C-to-G transversions
within distinct DNA trinucleotide contexts (preferentially 5’-TCA and 5’-TCG). Genomic C-to-U deamination events
within the same trinucleotide contexts also lead to cytosine mutation clusters (kataegis), and may precipitate visible
chromosomal aberrations such as translocations. Clinical studies indicate that APOBEC3B upregulation correlates with
poorer outcomes for estrogen receptor-positive breast cancer patients, including shorter durations of disease-free
survival and overall survival after surgery. APOBEC3B may therefore have both diagnostic and prognostic potential.
APOBEC3B may also be a candidate for therapeutic targeting because inhibition of this non-essential enzyme is
predicted to decrease tumor mutation rates and diminish the likelihood of undesirable mutation-dependent
outcomes such as recurrence, metastasis, and the development of therapy resistant tumors.Introduction - passive versus active mutational
processes in cancer
During all developmental stages, even when cells are not
actively dividing, our DNA is subjected to continual
damage by a wide variety of agents and mechanisms. The
majority of these insults are mitigated by DNA repair pro-
cesses, which usually restore the original DNA sequence
in an error-free manner. However, some DNA damage
events escape repair and manifest as somatic mutations.
These mutations, by and large, occur randomly across the
genome over the course of an individual’s lifetime. In
some instances, however, the 'wrong combination' of som-
atic mutations can transform a normal cell into a tumor
cell (Figure 1). The ongoing accumulation of additional
mutations also contributes to the growth of local tumor
cells, the development of metastatic outgrowths, and the
emergence of therapy resistance.Correspondence: rsh@umn.edu
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[1-3]. This review discusses the likelihood that a consid-
erable proportion of this heterogeneity and associated
phenotypes are due to a dominant acting enzyme called
apolipoprotein B editing catalytic subunit 3B (APOBEC3B;
see Box 1) that deaminates genomic DNA cytosines, pro-
motes higher than normal mutation rates, and thereby
enables accelerated tumor evolution. APOBEC3B does not
fit into classical tumor suppressor/oncogene paradigms.
Rather, it defines a new class of cancer facilitator, a type of
'enabling characteristic' [4], because it promotes the gen-
etic diversity that provides tumors with increased adaptive
capabilities. For instance, in contrast to kinase activation,
which can provide a tumor cell and all of its descendants
with a measurable growth advantage, APOBEC3B will
cause a different repertoire of mutations in every cell it
affects. APOBEC3B could have been responsible for the
initial kinase activating mutation, as well as additional
genetic changes that occur in descendent cells, including
therapy resistance mutations, especially if they confer a
selective advantage. However, APOBEC3B will not conferensee has exclusive rights to distribute this article, in any medium, for 6 months
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Figure 1 Ongoing mutation drives cellular transformation. A cartoon depicting the transformation of a normal cell into a mass of tumor cells.
Cellular changes are represented by altered morphologies and ever-increasing shades of red, due to ongoing mutational processes represented by
the inset arrow.
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expressed; rather, the compounded effects of the somatic
mutations will dictate the overall phenotype of each cell
and the larger tumor.
Before proceeding, it is important to distinguish somatic
and germline mutations. Germline mutations are inherited
from our parents. These are most frequently passed from
generation to generation in a Mendelian manner, but
they can also arise de novo in our parent’s germ cells.
The best-known examples in breast cancer occur in the
BRCA1 and BRCA2 genes [5]. Mutations in BRCA1 and
BRCA2 can compromise recombination repair, which
results in elevated rates of some types of DNA damage
and, consequently, an elevated risk of acquiring a cancer-
ous combination of mutations [6]. Additional common
inherited DNA repair defects are unlikely to have major
roles in breast cancer, although corrupted DNA repair
processes clearly contribute to many other tumor types. A
prominent example is inherited defects in mismatch repair
(MMR), which cause persistence of DNA replication
errors, elevated mutation rates, and predisposition to
colorectal tumors [7]. Moreover, BRCA2 is also known as
FANCD1, because some mutations in this gene predispose
to a syndrome called Fanconi anemia, characterized by
bone marrow failure and blood cancer [8]. In comparison,
somatic mutations occur during all stages of development,
including carcinogenesis. These mutations are attributable
to diverse types of DNA damage that by genetic or sto-
chastic means escape repair.
The recombination and mismatch repair processes
discussed above can be considered ‘passive mutational
processes’, and the DNA repair enzymes involved genomic
‘custodians’ or ‘caretakers’ [6,9]. The sum of all DNAdamage events that escape repair can be considered, for
lack of a better term, the spontaneous mutation level.
These passively and randomly acquired mutations will
happen regardless of other factors and, therefore, are
largely ‘unavoidable’. The overall spontaneous mutation
level and the associated composite mutation pattern are
therefore expected to be similar from person to person
within the human population. Defects in a particular
repair process will result in an elevation of the type(s) of
DNA damage typically repaired by this system.
In contrast, a growing number of DNA damage sources
can be considered ‘active mutational processes’. Accord-
ingly, these processes may be ‘avoidable’ (at least, in theory).
Well-known external DNA damaging agents are ultraviolet
light (UV) and tobacco compounds such as nicotine-
derived nitrosamine ketone (NNK), which are associated
with skin and lung cancers, respectively [10,11]. UV causes
DNA pyrimidine dimers (C∧C, C∧T, T∧C, and T∧T), which
are substrates for nucleotide excision repair [10]. However,
a lapse in error-free repair allows pyrimidine dimers to
persist and template the insertion of adenine bases during
lesion by-pass DNA replication (Figure 2a). If an adenine
base becomes ‘mispaired’ with a UV-linked cytosine, the
next round of DNA replication or repair yields a C-to-T
transition mutation in a dipyrimidine context. NNK from
tobacco smoke can become activated and alkylate guanine
bases (*G) [11]. These adducts are ‘read’ poorly by DNA
replication polymerases, resulting in *G/A mispairs that
lead to G-to-T transversion mutations. This type of
tobacco-induced mutation is not known to occur within
any particular DNA sequence context [12].
In addition to avoidable external sources of mutation,






















Figure 2 Local mutation preferences for UV-A and APOBEC3B-induced mutagenesis. Top row (a): ultraviolet (UV)-A crosslinks adjacent
pyrimidine bases (lesion depicted by double dash sign (=)). Several DNA polymerases will bypass this lesion by inserting two adenines. Excision repair
or another round of DNA replication will convert these C/A mispairs into C-to-T transition mutations. Bottom row (b): APOBEC3B (A3B) catalyzes the
hydrolytic deamination of single-stranded DNA cytosine into uracil (lesion depicted in biochemically preferred 5’-TCA context). Uracil in DNA is
recognized as a ‘normal’ thymine by DNA polymerases, and it therefore templates the insertion of an adenine in the complementary DNA strand.
Uracil base excision repair or another round of DNA replication will convert the U-A base pair into a C-to-T transition mutation. Additional mutagenic
outcomes are depicted in Figure 3.
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translesion synthesis (TLS) DNA polymerases including
POL κ (kappa), POL ι (iota), POL η (eta), POL ζ (zeta),
and REV1, which are low fidelity enzymes that lack the
capacities to proofread and perform processive DNA
synthesis [13]. These enzymes are recruited to sites of
DNA damage to temporarily take the place of a replicative
DNA polymerase and perform lesion bypass synthesis.
For example, as a specialized excision repair component
POL η will usually insert the correct DNA base opposite
UV-induced pyrimidine dimers [14], but other DNA
POLs, such as the major replicative polymerases δ and ε,
and the TLS POL κ are not adapted to this type of lesion
and have a tendency to insert adenine bases that result in
hallmark C-to-T transitions [15] (Figure 2a). The existence
of these mechanisms can be rationalized by the fact that
lesion bypass synthesis is relatively benign in comparison
to a failure to complete DNA replication before cell
division. Notably, multiple DNA polymerases also have
important roles in developing B lymphocytes by contribut-
ing to somatic hypermutation and the overall process of
antibody diversification and affinity maturation, which,
interestingly, is initiated by the APOBEC-related DNA
cytosine deaminase AID (activation-induced DNA cyto-
sine deaminase) [16] (elaborated below). As enzymatic
sources of mutation, DNA polymerases are theoretically
inhibitable and their mutagenic contributions preventable,
although the consequences of doing so may be undesirable
at the organismic level because the benefits of copying
DNA, bypassing DNA lesions, as well as generating adap-
tive immunity through antibody diversification may far
outweigh the disadvantages of inhibiting these processes
(even selectively or transiently).
Recent work has resulted in the discovery of APO-
BEC3B as an active, enzymatic source of mutation in
breast cancer [17]. APOBEC3B was described originally
as an antiviral enzyme, and a member of a larger family
of DNA cytosine deaminases [18]. APOBEC3B uses
water to catalyze the conversion of cytosine to uracilbases in single-stranded DNA. Uracil in DNA is a pre-
mutagenic lesion because DNA polymerases ‘read’ it as
thymine and pair it properly through two hydrogen bonds
to adenine during DNA replication (Figure 2b). Thus, one
of several hallmarks of APOBEC3B mutagenesis is C-to-T
transition mutations within specific local DNA sequence
contexts based on the intrinsic biochemical nature of the
deaminase itself (elaborated below).
Discovery and biological functions of
enzyme-catalyzed DNA cytosine deamination
Humans have the potential to encode up to nine enzymes
with DNA cytosine deaminase activity (APOBEC1, AID,
and APOBEC3A/B/C/D/F/G/H), as well as two related
proteins that have yet to elicit this activity (APOBEC2 and
APOBEC4) [18]. The DNA cytosine deaminase activity of
APOBEC1, AID, and several APOBEC3 enzymes was
discovered originally using an Escherichia coli-based drug
resistance assay [19,20]. Like all organisms, this bacterium
has a characteristic mutation frequency, and cells express-
ing AID, APOBEC1, APOBEC3C, or APOBEC3G were
shown to elicit 4- to 20-fold higher mutation frequencies.
E. coli engineered to lack the uracil-specific DNA repair
enzyme uracil DNA glycosylase (UDG) also have higher
mutation frequencies. However, the combination of
APOBEC expression and UDG deficiency caused syn-
ergistic increases in mutation frequency, in some
instances >100-fold, demonstrating that these proteins
catalyze C-to-U lesions in DNA and that uracil base
excision repair counteracts most of the damage [19,20].
In addition, each APOBEC3 enzyme was shown to
induce a distinct spectrum of drug-resistance mutations.
AID preferentially caused mutations at cytosine bases
preceded by purines (5’-AC and GC), APOBEC1 at
cytosines preceded by thymines (5’-TC), APOBEC3C
also at cytosines preceded by thymines but with a more
relaxed distribution (5’-TC), and APOBEC3G uniquely
at cytosines preceded by another cytosine (5’-CC).
These data indicated that the DNA cytosine deamination
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and, importantly, that each enzyme has distinct intrinsic
local substrate preferences. Subsequent studies have
demonstrated DNA cytosine deaminase activity for all
human APOBEC family members, except APOBEC2 and
APOBEC4, in analogous mutator assays, biochemical
studies with recombinant enzymes, and a variety of bio-
logical systems [18].
The DNA cytosine deaminase activity of AID is essen-
tial for antibody gene diversification through the distinct
processes of somatic hypermutation and class switch re-
combination [16]. In antigen responding B lymphocytes,
AID catalyzed C-to-U lesions in expressed heavy and
light chain variable regions are processed by uracil base
excision repair, MMR, and TLS polymerases into all six
types of base substitutions. This mutagenic process is
coupled to a selection process for B cells expressing
antibodies with higher affinities for foreign antigen and
results in large numbers of mutations within antibody
gene variable regions. Simultaneously, AID catalyzed C-
to-U lesions in switch regions of the expressed heavy chain
gene are also processed by uracil base excision repair
and MMR proteins into DNA breaks, which lead to
recombination of upstream and downstream switch
regions and expression of a new antibody isotype. Although
these processes are complex, they are relevant here because
they provide critical precedents for DNA deamination-
induced mutagenesis in cancer, most importantly by
demonstrating that uracil lesions can lead to both
simple and complex mutational outcomes dependent
upon downstream ‘repair’ processes. Moreover, consider-
able evidence indicates that misprocessed AID-catalyzed
deamination events at immunoglobulin loci, as well as
off-target deamination events, contribute to B cell
lymphomas [21].
APOBEC1, the namesake, is the only family member
with physiologically confirmed RNA substrates. APOBEC1
and editing cofactors are required for converting APOB
mRNA C6666 into uracil, which yields a premature
stop codon and a truncated APOB protein [22]. RNA
sequencing comparisons of wild-type and Apobec1-null
mice have revealed dozens more editing events, mostly
in mRNA 3’ untranslated regions with unclear functional
roles [23]. However, APOBEC1 is also a potent DNA C-
to-U editing enzyme [19,24], with likely roles in innate
immunity (related to APOBEC3 proteins discussed below)
[18,25]. Moreover, dysregulated APOBEC1 may also play
a part in cancer mutagenesis because its overexpression
in transgenic mice has been shown to induce liver and
colon tumors [26]. At least for mice, deep sequencing
has yet to determine whether this cancer association is
due to DNA and/or RNA cytosine editing activity.
However, recent biochemical, computational, and func-
tional experiments have implicated human APOBEC1 inesophageal adenocarcinomas, and tended to favor a DNA
deamination mechanism [27].
Over 1,000 studies this past decade have focused on
APOBEC3 enzymes because they have the remarkable
capability to deaminate retrovirus and retrotransposon
cDNA replication intermediates [18,25,28]. Most studies
to date have focused on the mechanism of HIV-1 restric-
tion. The current model posits that APOBEC3D/F/G/H
package into assembling viral particles, travel with the
particles until a new target cell is infected, and then
deaminate nascent viral cDNA cytosines during reverse
transcription. The resulting viral cDNA uracils then
template the insertion of genomic strand adenines, and
immortalize the original lesions as G-to-A mutations.
Unrestrained APOBEC3 activity can completely inactivate
HIV-1, but this rarely occurs in vivo because the viral
protein Vif nucleates the formation of an E3 ubitquitin
ligase complex that protects the genetic integrity of the
virus by degrading the APOBEC3 enzymes. Nevertheless,
APOBEC3 associated G-to-A mutations are frequently
observed in viral sequences from infected patients, imply-
ing that this mutagenic process may actually facilitate
HIV-1 pathogenesis by contributing to virus evolution,
immune escape, and drug resistance. APOBEC3 proteins
have also been implicated in restricting a large number of
DNA-based parasites, including cancer-associated viruses
Epstein-Barr virus, hepatitis B virus, human papilloma
virus, and human T-lymphotropic virus-1 [18,25,28]. The
prevailing model indicates that the entire APOBEC family
provides an overlapping innate immune defense to a wide
variety of known and likely many more unknown DNA-
based parasites.
Discovery and mechanism of APOBEC3B
mutagenesis in breast cancer
Over the past several years, multiple lines of evidence
have hinted at a novel enzymatic process in cancer muta-
genesis and inspired experiments to directly test an
APOBEC mutator hypothesis. First, initial speculations
were provoked by the discovery of a family of enzymes
with DNA deaminase activity and distinct local prefer-
ences [19,29,30]. Second, array hybridization experiments
suggested upregulation of at least one APOBEC3 in
several cancers [19]. Third, precedents established by AID
indicated that chromosomal DNA could be susceptible to
enzymatic deamination [16]. Fourth, genetic experiments
in yeast indicated that APOBEC3 enzymes could mutate
the genomic DNA of a eukaryote [31]. Fifth, early cancer
gene DNA sequencing studies using Sanger methodology
revealed mutation patterns biased to cytosine bases
[32-34]. Sixth, biochemical studies showed that methyl-
cytosine is more prone to spontaneous deamination
than normal cytosine [35], yet in many breast tumors
the majority of mutations do not occur at potentially
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strand-coordinated cytosine mutation clusters could be
induced by chemicals or APOBEC3G overexpression in
yeast selection experiments [36,37], and analogous clusters
biased to 5’-TC dinucleotides were discovered by deep-
sequencing breast and other cancer genomes [36,38,39].
Such mutational clusters have been termed kataegis,
due to a likeness with the concentration and intensity
of thundershowers [38]. It is important to note that
although each of these studies supports, to varying
degrees, a role for enzymatic DNA cytosine deamination
in cancer mutagenesis, none was demonstrative and other
mechanisms were plausible [40].
The hybridization and sequencing studies cited above,
plus availability of matched normal and tumor tissues
and a wide variety of cell lines, indicated that breast can-
cer might provide an opportunity to test an APOBEC3
mutator hypothesis. Quantitative PCR assays were used
to determine which APOBEC3 family members are
expressed in cancerous breast tissues in comparison with
matched adjacent or contralateral normal breast tissues
[17]. Several family members were expressed weakly or
undetectably in both tissue types (AID, APOBEC1,
APOBEC2, and APOBEC4), and others were expressed
similarly in both tissue types (APOBEC3A/D/F/G/H).
APOBEC3C was expressed at lower levels in tumor tis-
sues. Only one family member, APOBEC3B, was expressed
at significantly higher levels in tumor tissues in compari-
son with matched normal tissues, and it was barely detect-
able in normal breast tissues [17]. Similar proportions and
magnitudes of APOBEC3B overexpression were evident in
RNA sequencing data sets from independent tumors [17].
Moreover, nearly two-thirds of all breast cancer cell lines
showed upregulated levels of APOBEC3B in comparison
with control lines such as MCF10A [17]. Taken together,
these data showed that APOBEC3B is significantly and
constitutively upregulated in a large proportion of breast
tumors and cancer cell lines.
Two additional lines of evidence strongly linked APO-
BEC3B overexpression to breast cancer mutagenesis.
First, elevated APOBEC3B expression levels correlated
with higher C-to-T and overall base substitution muta-
tion loads [17]. These analyses were done by comparing
APOBEC3B mRNA levels and tumor mutation counts.
A significant positive correlation was observed for the
entire cohort, but correlations were clearest upon com-
parison of pooled data from the bottom and top third
of APOBEC3B expressing patients. The top third has a
median of 30 C-to-T mutations per exome, whereas the
lower third has less than 20. Moreover, the top third
has a median of nearly 70 base substitutions per exome,
whereas the lower third has less than 40 (these differ-
ences are explained in a model below). Second, a series
of biochemical experiments was done with the catalyticdomain of APOBEC3B to deduce its intrinsic DNA
cytosine deamination preference or ‘signature’ in vitro, and
this was shown to closely resemble the actual cytosine
mutation pattern in breast tumors [17]. Specifically, recom-
binant APOBEC3B preferred to deaminate cytosines within
5’-TCA and 5’-TCG motifs at least 5-fold and, in many
instances, >50-fold better than any other trinucleotide-
containing single-stranded DNA. The same two trinu-
cleotides, 5’-TCA and 5’-TCG, were the most commonly
mutated cytosine-containing motifs in two independent
breast cancer mutation data sets.
Finally, genetic knockdown experiments were used to
demonstrate that APOBEC3B is responsible for elevated
levels of DNA damage and mutation in several breast
cancer cell lines [17]. APOBEC3B mRNA knockdown
caused a corresponding depletion of all measurable DNA
deaminase activity in breast cancer cell line nuclear
extracts. APOBEC3B knockdown cells also had lower
steady state levels of genomic uracil as quantified by mass
spectrometry and lower mutation frequencies as judged
by drug resistance experiments. Moreover, fewer C-to-T
mutations were found in the TP53 and c-MYC genes of
APOBEC3B-depleted cells in comparison with controls.
Independent studies have since implicated APOBEC3B
mutagenesis in other types of cancer, including head/
neck, lung, bladder, cervical, ovarian, and as many as 16
out of 30 cancers examined to date [41-47]. Additional
work with yeast has suggested that both the immediate
product of DNA deamination, uracil, and the derivative
downstream lesion, the abasic site, may be important
intermediates in APOBEC3B mutagenesis [48,49]. Specif-
ically, expression of various APOBEC3 family members in
yeast induced high levels of C-to-T and C-to-G mutations,
as well as kataegic clusters, and deleting uracil DNA
glycosylase collapsed the mutation pattern to dispersed
C-to-T mutations. Deletion of the TLS DNA polymerase
REV1 as well as expression of a REV1 catalytic mutant
also caused similar phenotypes. Therefore, C-to-G trans-
versions in yeast are most likely due to REV1-dependent
deoxy-cytidine insertion opposite an abasic site created by
the combined action of APOBEC3B deamination and
UDG base excision. Kataegis events most likely require
APOBEC3B at two levels, first to create a lesion that
results in the initial single- or double-stranded DNA
break, and second to deaminate (perhaps processively) the
resulting exposed single-stranded DNA repair intermedi-
ates. Because UDG is uniquely able to excise uracils from
both double- and single-stranded DNA substrates, these
clustered DNA C-to-U lesions lead to both C-to-T transi-
tions and C-to-G transversions depending on the poly-
merase recruited to assist with repair. An additional
feature of kataegis is a strong DNA strand bias with most
cytosine mutations occurring on the same strand, likely
reflecting the existence of an extensive single-stranded
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that a U/G mismatch in transfected plasmid DNA can
lead to single-stranded regions susceptible to APOBEC3-
mediated deamination [50].
Overall, a compelling case has been made for APO-
BEC3B mutagenesis in breast and additional cancers.
These studies have led to a model in which APOBEC3B-
dependent DNA C-to-U deamination events underlie a
variety of mutagenic outcomes (Figure 3; based on
[17,41,43]). As discussed, uracils can directly template
the insertion of adenines during DNA replication or
local DNA synthesis. However, based on studies in yeast
[48] and the fact that UDG is a very efficient enzyme
that excises uracils from both single- and double-stranded
DNA [51], it is likely that abasic sites are major intermedi-
ates for both dispersed and clustered C-to-T mutations
and C-to-G mutations. Most polymerases will follow the
‘A-rule’ and insert an A opposite an abasic site, accounting
for C-to-T transitions, whereas REV1 will uniquely insert
a C opposite an abasic site, which accounts for C-to-G
transversions. An additional DNA polymerase may also be
involved because C-to-A mutations have been observed in
other APOBEC3B-associated cancers such as ovarian
carcinomas [43,45]. Uracil excision followed by abasic siteTCACGA
A G T G C T
TUACGA
A G T G U T
A3B UDG
Figure 3 Model for APOBEC3B mutagenesis in cancer. The central path
excision repair of two C-to-U lesions catalyzed by APOBEC3B (A3B). Most gen
in this repair process can lead to a variety of mutagenic outcomes. Top left: C
(as in Figure 2) or from synthesis over an abasic site because most DNA polym
Bottom left: C-to-G transversions most likely occur when REV1 inserts deoxy-c
a round of DNA synthesis. Top right: a single-stranded DNA break (SSB) can re
component of BER). Bottom right: A double-stranded DNA break (DSB) can re
DNA replication fork hitting a single-stranded break. Both single- and double-
kataegis (A3B-catalyzed deamination of exposed single-stranded DNA) and in
DNA ligase; POL, polymerase; UDG, uracil DNA glycosylase.processing by the major abasic site endonuclease, APEX,
will generate a single-stranded break that could easily be
processed into a double-stranded break by a variety of
mechanisms, including the generation of a nick on the
opposing strand or a replication fork collision. Nucleolytic
resection of nicked or broken DNA may create single-
stranded DNA substrates for APOBEC3B. As additional full
genome sequences become available, it will be interesting
to determine whether larger-scale chromosomal aberrations
such as insertions, deletions, translocations, and amplifica-
tions correlate with APOBEC3B expression and/or define
hotspots for dispersed or clustered APOBEC3B deamin-
ation events. Initial studies with breast cancer genomic
DNA sequences have indicated that a portion of kataegis
events may be located near sites of DNA rearrangement
[36,38,52], although global levels of segmental copy number
changes do not appear to correlate [44].
Possible involvement of at least one other APOBEC
family member in breast cancer mutagenesis
APOBEC3B is absent from a substantial fraction of the
global population due to a 29.5 kb deletion allele that joins
the homologous 3’ untranslated regions of APOBEC3A
and APOBEC3B and removes the entire coding sequenceT ACGA
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way goes left to right and then circles back to depict error-free base
omic uracils are probably repaired in this manner. However, intermediates
-to-T mutations can result from DNA synthesis over uracilated templates
erases insert deoxy-adenosine opposite this non-instructional lesion.
ytidine opposite an abasic site followed by repair of the original lesion or
sult from cleavage of the phosphodiester backbone by APEX (normal
sult from opposing APEX-mediated endonucleolytic cleavages, or from a
stranded breaks can lead to additional mutagenic outcomes such as
sertions, deletions, amplifications, inversions, and translocations. LIG,
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Oceanic populations (93%), intermediate in Asian and
North American Indian populations (37% and 58%), and
rare in European and African populations (6% and 1%).
This natural deletion allele provides clear opportunities
for both molecular and clinical studies. A recent study
showed that 5’-TC biased mutations and kataegis are still
prevalent in a small number of breast tumors in the
complete absence of APOBEC3B [54]. At first glance,
this observation calls into question the aforementioned
work. However, only 14 APOBEC3B-null breast cancers
could be identified for analysis and tumor ages were
unknown, making mutation frequency comparisons diffi-
cult. Therefore, the most parsimonious explanation at this
time is that APOBEC3B and at least one additional family
member contribute to mutagenesis in breast cancer.
The most likely candidates based on intrinsic DNA
deamination preferences for 5’-TC motifs are APOBEC1
and/or APOBEC3A/C/D/F/H [18]. In particular, APO-
BEC3A may be dysregulated through fusion with the
APOBEC3B 3’ untranslated region, poly-A region, and
potential 3’ cis-regulatory sequences [54,55]. Consistent
with this idea, several studies have shown that APOBEC3A
overexpression can induce DNA damage responses result-
ing in the appearance of classical markers, double-stranded
breaks, and elevated levels of mutation [17,56-61]. All of
these studies have relied upon APOBEC3A overexpression
in heterologous cell types, and it should be noted that
endogenous APOBEC3A is not genotoxic even upon 100-
fold upregulation by interferon-α [62,63]. Viral infections
causing innate immune responses and/or splice variants
may also be contributing factors. In support of this idea,
recent studies on head/neck cancer have linked human
papilloma virus infection to APOBEC3B upregulation, and
one has shown that the viral E6 oncoprotein is sufficient
to trigger APOBEC3B upregulation [46,64,65]. Hit-and-
run infections causing transient APOBEC3 upregulation
are also plausible but challenging to test. A current limita-
tion is a lack of specific antibodies to many of the human
APOBEC3 family members, including APOBEC3B, which
if available would enable protein level studies to be
compared with current mRNA-based work. In any event,
additional work including clinical studies in appropriate
ethnic populations will be necessary to generate larger
cohorts of APOBEC3B-null individuals for expression
studies, mutation pattern analyses, and possibly definitive
functional experiments to unambiguously delineate the in-
volvement of other family members in cancer mutagenesis.
Clinical impact of APOBEC3B mutagenesis in breast
cancer - major differences between incidence and
progression
Incidence and progression are separate topics that do
not necessarily have to share molecular mechanisms.Incidence is the probability of getting cancer. Progression
is what happens after a cancer occurs. A priori, one would
predict that APOBEC3B status would not impact cancer
incidence because at least one upstream event is needed
to elevate APOBEC3B expression [17]. However, three
independent studies have indicated that homozygosity
for the APOBEC3B null allele associates with a higher
incidence of breast cancer [66-68]. The largest study
showed that the risk of developing breast cancer was
higher for those with homozygous null alleles than for
heterozygous carriers or individuals with two copies of
the intact gene [67]. Given the innate immune functions
of APOBEC3B with clear antiviral and antitransposon
activities [18,25,28], it is possible that APOBEC3B-null indi-
viduals have less protection from an as-yet-unidentified
virus or they have chronically higher levels of endogenous
transposition (events that would otherwise be restricted),
which is another way to endow cells with a mutator pheno-
type. Indeed, higher levels of L1 transposition have been
documented in some types of cancer [69] but association
with APOBEC3B nullizygosity has yet to be addressed.
Recent work has addressed the question of progression
in a large cohort of estrogen receptor-positive breast
cancer patients [70]. APOBEC3B mRNA levels in previ-
ously cryopreserved samples were measured by quantitative
PCR and the overall cohort average was used to divide high
and low expression groups. Kaplan-Meier analyses were
done to compare the two groups, and high APOBEC3B
levels were found to associate with shorter durations of
both disease-free survival and overall survival. Moreover,
because these specimens were procured some time ago,
outcomes were not complicated by adjuvant treatments.
Therefore, these data indicate that APOBEC3B levels may
be a pure prognostic marker for estrogen receptor-positive
breast cancers. Similar results were obtained by retrospect-
ively analyzing independent cohorts. Additional work and
possibly prospective trials will be needed to evaluate estro-
gen receptor-negative breast cancers and deduce potential
interactions with adjuvant therapies. For instance, studies
will be needed to address whether elevated levels of
APOBEC3B-enabled mutation contribute to the develop-
ment of drug resistance and metastases.
Conclusions
The DNA cytosine deaminase APOBEC3B is a newly
defined source of DNA damage and mutation in breast
cancer. It is already clear that APOBEC3B mutagenesis
impacts approximately half of all breast cancers and may
be responsible for large proportions of mutations in these
tumors, ranging from modest to extremely high levels.
Because APOBEC3B is an endogenous and likely stochastic
mutagen, it is predicted to drive tumor evolution and con-
tribute to all processes attributable to mutations (that is,
tumor development, progression, heterogeneity, metastasis,
Harris Breast Cancer Research  (2015) 17:8 Page 8 of 10and drug resistance). In fact, a recent study with head/neck
cancer implicated APOBEC3B mutagenesis in activation
of the kinase PIK3CA, which is also mutated in a large
proportion of breast cancers [46].
To use UV light as an analogy, knowledge of its pro-
mutagenic activity led to the development of measures
to limit exposure and reduce the risk of potentially detri-
mental long-term outcomes such as skin cancer (notably
sunscreen). APOBEC3B may be of similar importance to
breast cancer, and one can already envisage developing
the equivalent of a ‘sunscreen’ to inhibit APOBEC3B
mutagenesis. APOBEC3B may be a prime therapeutic
target because it is non-essential, it is rarely expressed in
most normal tissues, and it is a dominant-acting enzyme
with an active site that may be druggable. Proof-of-
concept inhibitors have already been developed for the
related enzyme APOBEC3G [71,72]. Additional work is
likely to yield APOBEC3B inhibitors, and such molecules
may have therapeutic merit in high-risk individuals and/
or as a post-operative adjuvant to limit further tumor
evolution and improve the durability and efficacy of
existing therapeutics.
APOBEC3B may also have diagnostic and prognostic
utility. Direct measurements of APOBEC3B mRNA or
protein levels, perhaps in combination with ‘reading’ its
mutagenic signature, would allow tumors to be grouped
into APOBEC3B risk categories (analogous to assays for
microsatellite instability in MMR-defective cancers). Such
studies may determine a threshold value for APOBEC3B
expression that unambiguously distinguishes a rapidly
evolving cancer from an indolent mass. False positive
breast cancer diagnoses still occur and molecular informa-
tion on APOBEC3B may help reduce the magnitude of
this problem. Appropriate diagnostic assays will also
be necessary to identify cancer cases that may benefit
from APOBEC3B inhibition. In conclusion, APOBEC3B
mutagenesis is a major factor in breast cancer and
many other human malignancies and much additional
basic, translational, and clinical work is needed to fully
realize this discovery.Box 1
APOBEC stands for apolipoprotein B editing catalytic subunit but
the term ‘APOBEC’ is only appropriate for the founding member
of the family, APOBEC1, which does edit APOB mRNA; other family
members should be referred to as APOBEC-like or, ideally, by full
GenBank-designated names APOBEC3A, APOBEC3B, APOBEC3C,
APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC2,
APOBEC4, and AICDA, or by commonly used alphanumeric
acronyms, respectively A3A-H, A2, A4, and AID.)Abbreviations
AID: Activation-induced DNA cytosine deaminase; APOBEC: Apolipoprotein B
editing catalytic subunit; MMR: Mismatch repair; NNK: Nicotine-derived
nitrosamine ketone; POL: Polymerase; TLS: Translesion synthesis; UDG: Uracil
DNA glycosylase; UV: Ultraviolet.
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